Jazz Pharmaceuticals
JAZZ
384 hedge funds and large institutions have $5.75B invested in Jazz Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 138 increasing their positions, 147 reducing their positions, and 67 closing their positions.
15% more capital invested
Capital invested by funds: $5B → $5.75B (+$750M)
5.08% more ownership
Funds ownership: 89.24% → 94.33% (+5.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 147
6% less funds holding
Funds holding: 407 → 384 (-23)
30% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 67
53% less call options, than puts
Call options by funds: $22.4M | Put options by funds: $47.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$142M |
| 2 |
Millennium Management
New York
|
+$53.3M |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
+$51.9M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$40.1M |
| 5 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$36.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$60.2M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$46.3M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$33.4M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$26M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$24.2M |
JAZZ Hedge Fund Activity: Q2 2020 in Review
384 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2020, worth a combined $5.75B — up 15% from $5B a quarter earlier.
Sellers outnumbered buyers: 67 funds closed out of JAZZ and 47 opened new positions — a net loss of 20 holders — while 147 trimmed existing stakes and 138 added.
The largest buyer was Citadel Advisors, adding an estimated $142M. The largest seller was Congress Asset Management, cutting an estimated $60.2M.
- 384 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2020, down from 407 in Q1 2020.
- Funds reported $5.75B of Jazz Pharmaceuticals stock for Q2 2020, up 15% quarter-over-quarter.
- 47 funds opened new Jazz Pharmaceuticals positions in Q2 2020 and 67 closed out, a net change of -20 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2020 was Citadel Advisors, an estimated $142M added.
- The largest Jazz Pharmaceuticals seller in Q2 2020 was Congress Asset Management, an estimated $60.2M sold.
Based on aggregated 13F filings for Q2 2020.